<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Flumazenil: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Flumazenil: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Flumazenil: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8456" href="/d/html/8456.html" rel="external">see "Flumazenil: Drug information"</a> and <a class="drug drug_patient" data-topicid="12497" href="/d/html/12497.html" rel="external">see "Flumazenil: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708776"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Seizures:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of flumazenil has been associated with the occurrence of seizures. These are most frequent in patients who have been on benzodiazepines for long-term sedation or in overdose cases where patients are showing signs of serious cyclic antidepressant overdose. Practitioners should individualize the dosage of flumazenil and be prepared to manage seizures.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1052814"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidote, Benzodiazepine</span></li></ul></div>
<div class="block don drugH1Div" id="F53462456"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="68cd4cd4-992a-4557-9cee-9ebd0bed9663">Benzodiazepine reversal</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benzodiazepine reversal:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Intermittent repeat IV bolus doses</i>: Limited data available: Initial dose: IV: 0.01 to 0.02 mg/kg/dose given over 15 seconds; may repeat 0.01 mg/kg after 30 to 45 seconds after initial dose, and then every minute to a maximum cumulative dose of 0.05 mg/kg or 1 mg total, whichever is lower (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Hansen.1','lexi-content-ref-Howland.1','lexi-content-ref-2005661','lexi-content-ref-9306053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Hansen.1','lexi-content-ref-Howland.1','lexi-content-ref-2005661','lexi-content-ref-9306053'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Continuous IV infusion (as an alternative to repeat bolus doses)</i>: Very limited data available; Initial rate: IV: 0.005 to 0.01 mg/kg/<b>hour</b>; infusion rates of 0.05 mg/kg/<b>hour</b> for 6 hours have also been reported; dosing based on case reports in newborns (including a premature neonate [GA: 32 weeks]) exposed to high doses of diazepam intrapartum (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8319721','lexi-content-ref-9512213','lexi-content-ref-2005661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8319721','lexi-content-ref-9512213','lexi-content-ref-2005661'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c03fcf59-d545-459d-9641-13f0cff96b73">Myoclonus, benzodiazepine-induced</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Myoclonus, benzodiazepine-induced:</b> Very limited data available: Term neonates: IV: 0.0078 mg/kg as a single dose was effective in one full-term neonate who was receiving continuous infusion midazolam (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11349753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11349753'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F172050"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27d33e7f-aa72-4eeb-b935-6e44425c0d43">Benzodiazepine intoxication/overdose</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benzodiazepine intoxication/overdose:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Consult a clinical toxicologist or poison control center for guidance on patient selection for flumazenil therapy. The role of flumazenil in the poisoned patient, especially comatose patients and mixed overdose patients, remains controversial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8597142','lexi-content-ref-1611650','lexi-content-ref-8605789','lexi-content-ref-Williams.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8597142','lexi-content-ref-1611650','lexi-content-ref-8605789','lexi-content-ref-Williams.1'])">Ref</a></span>). Flumazenil should not be used with unknown ingestions or in patients with any of the following: chronic maintenance with or physiologic dependence on benzodiazepines, receiving a benzodiazepine to treat a life-threatening condition, coingestion of a proconvulsant (eg, tricyclic antidepressants), or history of an underlying seizure disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22531190','lexi-content-ref-21785147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22531190','lexi-content-ref-21785147'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: Initial dose: 0.01 mg/kg; maximum dose: 0.2 mg/dose; may repeat every minute if needed to a maximum cumulative dose of 1 mg total (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Continuous IV infusion: 0.005 to 0.01 mg/kg/<b>hour</b> has been reported as an alternative to intermittent doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7739960','lexi-content-ref-2512053','lexi-content-ref-8177806']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7739960','lexi-content-ref-2512053','lexi-content-ref-8177806'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9801b6e-2a6b-4346-90ac-db5c46775d96">Benzodiazepine reversal, procedural sedation or general anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benzodiazepine reversal, procedural sedation or general anesthesia:</b> Infants, Children, and Adolescents: IV: Initial dose: 0.01 mg/kg; maximum dose: 0.2 mg/dose; given over 15 seconds; if needed, may repeat same dose after 45 seconds, and then every minute to a maximum cumulative dose of 0.05 mg/kg or 1 mg total, whichever is lower; usual total dose: 0.08 to 1 mg (mean: 0.65 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130532"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; adult pharmacokinetic data suggest drug not significantly affected by renal failure (CrCl &lt;10 mL/minute) or hemodialysis.</p></div>
<div class="block dohp drugH1Div" id="F51110627"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Initial reversal dose: Use normal dose; repeat doses should be decreased in size or frequency.</p></div>
<div class="block doa drugH1Div" id="F172031"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8456" href="/d/html/8456.html" rel="external">see "Flumazenil: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9801b6e-2a6b-4346-90ac-db5c46775d96">Benzodiazepine reversal, procedural sedation or general anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benzodiazepine reversal, procedural sedation or general anesthesia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 0.2 mg over 2 minutes; if the desired level of consciousness is not obtained after 1 minute, 0.2 mg may be repeated at 1-minute intervals up to 4 times; usual cumulative dosage range: 0.6 to 1 mg; maximum cumulative dose: 1 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Resedation:</i>
<b>IV: </b>In the event of resedation, repeat 0.2 to 1 mg doses (administered at 0.1 mg/minute) may be administered at 20-minute intervals as needed; maximum cumulative resedation dose: 3 mg in 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aba8af51-d46c-4df4-a68e-3d3789455abd">Benzodiazepine overdose, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Benzodiazepine overdose, treatment: Note: </b> Routine use of flumazenil is controversial, as most benzodiazepine-poisoned patients can be treated successfully with supportive measures alone, and use of flumazenil is associated with a risk of adverse effects (eg, withdrawal seizures, arrhythmias), especially in patients who have co-ingested a proconvulsant or proarrhythmic agent, patients that are physiologically dependent on benzodiazepines, or patients with an underlying seizure disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3142220','lexi-content-ref-Howland.1','lexi-content-ref-26096314','lexi-content-ref-33581937']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3142220','lexi-content-ref-Howland.1','lexi-content-ref-26096314','lexi-content-ref-33581937'])">Ref</a></span>). Consider consultation with poison control center or medical toxicologist; refer to institutional protocols.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 0.2 mg over 2 minutes; if the desired level of consciousness is not obtained 30 seconds after the dose, 0.3 mg can be administered over 3 minutes; if the desired level of consciousness is still not obtained, 0.5 mg can be administered over 5 minutes and repeated at 1-minute intervals; usual cumulative dosage range: 1 to 3 mg; usual cumulative maximum dose: 3 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Patients with a partial response to a cumulative dose of 3 mg may rarely require additional titration up to a total dose of 5 mg (although doses &gt;3 mg do not reliably produce additional effects). If a patient has not responded 5 minutes after a cumulative dose of 5 mg, benzodiazepines are likely not the major cause of sedation; sedation may be due to exposure to additional CNS depressants (eg, opioids).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Resedation:</i>
<b>IV: </b>In the event of resedation, repeat 0.5 to 1 mg doses (administered at 0.1 mg/minute) may be administered at 20-minute intervals as needed; maximum cumulative resedation dose: 3 mg in 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> After an overdose with a large dose of a benzodiazepine, the duration of a single dose of flumazenil is not expected to exceed 1 hour; if clinically necessary, the period of wakefulness may be prolonged with repeated low IV doses of flumazenil, or by an infusion of 0.1 to 1 mg/hour (off label) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1686131','lexi-content-ref-14620397','lexi-content-ref-33125517','lexi-content-ref-8605789']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1686131','lexi-content-ref-14620397','lexi-content-ref-33125517','lexi-content-ref-8605789'])">Ref</a></span>). Use of a continuous infusion of flumazenil has been associated with a reduction in the number of patients requiring intubation as compared to use of supportive care alone (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1686131','lexi-content-ref-33125517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1686131','lexi-content-ref-33125517'])">Ref</a></span>); consider consultation with a poison control center or medical toxicologist when selecting flumazenil dosing strategy.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="77b45b46-30ef-435e-b147-3613534ad39f">Nonbenzodiazepine hypnotic overdose or gabapentin overdose, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonbenzodiazepine hypnotic overdose or gabapentin overdose, treatment (off-label use):</b>
<b>Note:</b> May consider during the treatment of patients who are experiencing toxicity secondary to a nonbenzodiazepine hypnotic agent (eg, eszopiclone, zaleplon, zolpidem, zopiclone) or gabapentin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9865246','lexi-content-ref-12503937','lexi-content-ref-16235515','lexi-content-ref-12215053','lexi-content-ref-2111156','lexi-content-ref-7955804','lexi-content-ref-18788000']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9865246','lexi-content-ref-12503937','lexi-content-ref-16235515','lexi-content-ref-12215053','lexi-content-ref-2111156','lexi-content-ref-7955804','lexi-content-ref-18788000'])">Ref</a></span>). Limited data available; dose based on use in benzodiazepine overdose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 0.2 mg over 2 minutes; if the desired level of consciousness is not obtained 30 seconds after the dose, 0.3 mg can be administered over 3 minutes; if the desired level of consciousness is still not obtained, 0.5 mg can be administered over 5 minutes and repeated at 1-minute intervals; usual cumulative dosage range: 1 to 3 mg; usual maximum cumulative dose: 3 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Based on use in benzodiazepine overdose, patients with a partial response to a cumulative dose of 3 mg may rarely require additional titration up to a total dose of 5 mg (although doses &gt;3 mg do not reliably produce additional effects). If a patient has not responded 5 minutes after a cumulative dose of 5 mg, the major cause of sedation may be due to exposure to additional CNS depressants (eg, opioids).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Resedation:</i>
<b>IV: </b>In the event of resedation, repeat 0.5 to 1 mg doses (administered at 0.1 mg/minute) may be administered at 20-minute intervals if needed; maximum cumulative resedation dose: 3 mg in 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Howland.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Due to the short duration of sedation of nonbenzodiazepine hypnotics, a continuous infusion is probably unnecessary in patients intoxicated with these agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9865246','lexi-content-ref-23404347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9865246','lexi-content-ref-23404347'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991731"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling; however, pharmacokinetics are not significantly affected by renal failure (CrCl &lt;10 mL/minute) or hemodialysis.</p></div>
<div class="block doha drugH1Div" id="F50989059"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Initial reversal: No dosage adjustment necessary. Repeat doses: Reduce dose or frequency.</p></div>
<div class="block adr drugH1Div" id="F171998"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Gastrointestinal: Vomiting (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (1% to 3%), palpitations (3% to 9%), vasodilation (cutaneous) (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1% to 3%), xerostomia (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Inflammation at injection site (1% to 3%), injection-site reaction (1% to 3%, including skin abnormality), pain at injection site (3% to 9%), rash at injection site (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation (3% to 9%), anxiety (3% to 9%), asthenia (1% to 3%), ataxia (10%), depersonalization (1% to 3%), depression (1% to 3%), dizziness (10%), dysphoria (1% to 3%), emotional lability (1% to 3%), euphoria (1% to 3%), fatigue (1% to 3%), headache (1% to 3%), hypoesthesia (1% to 3%), insomnia (3% to 9%), malaise (1% to 3%), nervousness (3% to 9%), paranoia ideation (1% to 3%), paresthesia (1% to 3%), sensation disorder (1% to 3%), tremor (3% to 9%), uncontrolled crying (1% to 3%), vertigo (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (3% to 9%), diplopia (1% to 3%), lacrimation (1% to 3%), visual disturbance (1% to 3%), visual field defect (1% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (3% to 9%), hyperventilation (3% to 9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial arrhythmia, atrioventricular nodal arrhythmia, bradycardia, cardiac arrhythmia, chest pain, hypertension, premature ventricular contractions, tachycardia, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Hiccups</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Tongue edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Confusion, delirium, drowsiness, hyperacusis, lack of concentration, rigors, seizure, shivering, speech disturbance, stupor, voice disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory disturbance, reversible hearing loss, tinnitus</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Withdrawal syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Nervous system: Fear</p></div>
<div class="block coi drugH1Div" id="F172012"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to flumazenil, benzodiazepines, or any component of the formulation; patients administered benzodiazepines for control of potentially life-threatening conditions (eg, control of intracranial pressure or status epilepticus); patients who may have ingested or are showing signs of cyclic-antidepressant overdosage.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F171995"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Amnesia: Does not consistently reverse amnesia; patient may not recall verbal instructions after procedure.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving) for 24 hours after discharge.</p>
<p style="text-indent:-2em;margin-left:4em;">• Resedation: Occurs more frequently in patients where a large single dose or cumulative dose of a benzodiazepine has been administered along with a neuromuscular-blocking agent and multiple anesthetic agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory depression: Should not rely upon to reverse respiratory depression/hypoventilation. Flumazenil is not a substitute for evaluation of oxygenation. Establishing an airway and assisting ventilation, as necessary, is always the initial step in overdose management.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizures: <b>[US Boxed Warning]: Benzodiazepine reversal may result in seizures; seizures may occur more frequently in patients on benzodiazepines for long-term sedation or following tricyclic antidepressant overdose. Dose should be individualized and practitioners should be prepared to manage seizures.</b> Seizures may also develop in patients with concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration. Use with caution in patients relying on a benzodiazepine for seizure control.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Head injury: Use with caution in patients with a head injury; may alter cerebral blood flow or precipitate convulsions in patients receiving benzodiazepines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic dysfunction; repeated doses of the drug should be reduced in frequency or amount.</p>
<p style="text-indent:-2em;margin-left:4em;">• Panic disorder: Use with caution in patients with a history of panic disorder; may provoke panic attacks.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Drug/alcohol dependence: Use caution in drug and ethanol-dependent patients; these patients may also be dependent on benzodiazepines.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intensive care patients: Should be used with caution in the intensive care unit because of increased risk of unrecognized benzodiazepine dependence in such settings.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Should not be used to diagnose benzodiazepine-induced sedation. Reverse neuromuscular blockade before considering use. Flumazenil does not antagonize the CNS effects of other GABA agonists (such as ethanol, barbiturates, or general anesthetics); nor does it reverse opioids. Not recommended for treatment of benzodiazepine dependence.</p>
<p style="text-indent:-2em;margin-left:4em;">• Overdose use: Use with caution in patients with mixed drug overdoses; toxic effects of other drugs taken may emerge once benzodiazepine effects are reversed.</p></div>
<div class="block foc drugH1Div" id="F172006"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.5 mg/5 mL (5 mL); 1 mg/10 mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F171991"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323156"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Flumazenil Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5 mg/5 mL (per mL): $1.56 - $1.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg/10 mL (per mL): $1.56 - $8.20</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866921"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.1 mg/mL (5 mL)</p></div>
<div class="block admp drugH1Div" id="F52612854"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: For IV use only; administer by rapid IV injection over 15 to 30 seconds at a rate not to exceed 0.2 mg/minute; administer through a freely running IV infusion into larger vein (to decrease chance of pain, phlebitis).</p></div>
<div class="block adm drugH1Div" id="F172009"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer in freely running IV into large vein to minimize pain at the injection site. To decrease frequency of emergent confusion and agitation, administer at a rate of 0.1 mg/minute, especially with larger doses. May also administer at a rate of 0.2 mg/minute or as fast as 0.2 mg over 15 seconds; however, there may be an increase in adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27920113','lexi-content-ref-Howland.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27920113','lexi-content-ref-Howland.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F172022"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store at 20°C to 25°C (68°F to 77°F). Once drawn up in the syringe or mixed with D5W, LR, or NS, use within 24 hours. Discard any unused solution after 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 6 to 12 mg of flumazenil be stocked. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53566959"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Reversal of conscious sedation induced with benzodiazepines (FDA approved in ages 1 to 17 years); complete or partial reversal of the sedative effects of benzodiazepines used in conscious sedation and general anesthesia (FDA approved in adults); management of benzodiazepine overdose (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F7914344"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Flumazenil may be confused with influenza virus vaccine</p>
<p style="text-indent:2em;">Romazicon may be confused with rocuronium</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299345"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F172000"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block dic drugH1Div" id="F15962118"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid alcohol for the first 24 hours after administration or as long as the effects of benzodiazepines exist.</p></div>
<div class="block pri drugH1Div" id="F172014"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Teratogenic effects were not seen in animal reproduction studies. Embryocidal effects were seen at large doses. Use during labor and delivery is not recommended. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>
<div class="block mopp drugH1Div" id="F53566942"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Level of consciousness and resedation, blood pressure, heart rate, respiratory rate, continuous pulse oximetry; monitor for resedation for 1 to 2 hours after reversal of sedation in patients who receive benzodiazepine sedation.</p></div>
<div class="block pha drugH1Div" id="F171994"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competitively inhibits the activity at the benzodiazepine receptor site on the GABA/benzodiazepine receptor complex. Flumazenil does not antagonize the CNS effect of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (ethanol, barbiturates, general anesthetics) and does not reverse the effects of opioids</p></div>
<div class="block phk drugH1Div" id="F172011"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Follows a 2 compartment open model; Clearance and V<sub>d</sub> per kg are similar for children and adults, but children display more variability.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 1 to 2 minutes; 80% response within 3 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 6 to 10 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Resedation may occur after ~1 hour (range: 19-50 minutes); duration related to dose administered and benzodiazepine plasma concentrations; reversal effects of flumazenil may wear off before effects of benzodiazepine.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Initial V<sub>d</sub>: 0.5 L/kg; V<sub>dss</sub>: 0.9-1.1 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~50% (~67% of which is bound to albumin).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; dependent upon hepatic blood flow.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children: Terminal: 20 to 75 minutes (mean: 40 minutes).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Alpha: 4 to 11 minutes; Terminal: 40 to 80 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate hepatic dysfunction: 1.3 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: 2.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces; urine (&lt;1% as unchanged drug).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Dependent upon hepatic blood flow; Adults: 0.8 to 1 L/hour/kg.</p></div>
<div class="block phksp drugH1Div" id="F51192583"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: <b>Moderate: </b>Mean total clearance decreased 40% to 60%. <b>Severe:</b> Mean total clearance decreased 75%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F172015"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fadaflumaz | Flumazenil Surar | Lanexat</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil B.Braun | Flumazenil deltaselect | Flumazenil Hikma | Flumazenil kabi | Flumazenil pharmaselect</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Apo flumazenil | DBL Flumazenil | Flumazenil kabi</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil b. braun</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil kabi</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Flumazil | Flunexil | Lanexat | Lenazen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Flumazenil Actavis | Flumazenil Labatec | Flumazenil mepha | Flumazenil Sintetica</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Lanexat</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Lai yi</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Diazenil | Lanexat</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil pharmaselect</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil Actavis | Flumazenil b. braun | Flumazenil hexal | Flumazenil Inresa | Flumazenil pharmaselect | Flumazenil Teva</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Lanexat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil b. braun | Flumazenil fresenius kabi | Flumazenil pharmaselect | Mazenil</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenilo Actavis | Flumazenilo Braun | Flumazenilo Combino pharm | Flumazenilo fresenius kabi | Flumazenilo G.E.S. | Flumazenilo genfarma | Flumazenilo Hikma | Flumazenilo Teva</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Flumazenil b braun | Lanexat</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil Aguettant | Flumazenil dakota | Flumazenil kabi | Flumazenil panpharma | Flumazenil Teva | Flumazenil Winthrop</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Demoxate | Flumazenil/cooper | Flumazenil/kabi | Flumexat</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil kabi | Flumazenil pharmaselect</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Fludot</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil kabi | Flumazenil Teva</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Exitine | Flunexate</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Ansedative | Flunil | Lumasate | Luzenil | Newzenil</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Antadona | Lanexat | Outnestin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Antabenz | Flumazenil Hameln | Flumazenil kabi</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil Actavis | Flumazenil kabi</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil Actavis | Flumazenil b. braun | Flumazenil fresenius kabi | Flumazenil Hameln</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Lanexat</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil b. braun | Flumazenil kabi | Flumazenil pharmaselect</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Romazicon</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Lanexat</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Exitine | Mazenil</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Flumazenil pharmaselect</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Exitine</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Flumazenil Actavis | Flumazenil b. braun | Flumazenil fresenius kabi | Flumazenil Hameln | Lanexat</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Anexate | Demoxate | Flumazenil panpharma</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anesed r | Anexate | Denaksat | Fluxate | Lauzenil | Mazenil</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Flumazenilo icu vita | Flumil | Lanexat</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Flumazepin | Lanexat</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Anexate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-27920113">
<a name="27920113"></a>An H, Godwin J. Flumazenil in benzodiazepine overdose. <i>CMAJ</i>. 2016;188(17-18):E537. doi:10.1503/cmaj.160357<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/27920113/pubmed" id="27920113" target="_blank">27920113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003, 67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9865246">
<a name="9865246"></a>Burton JH, Lyon L, Dorfman T, Tomassoni AJ. Continuous flumazenil infusion in the treatment of zolpidem (Ambien) and ethanol coingestion. <i>J Toxicol Clin Toxicol</i>. 1998;36(7):743-746. doi:10.3109/15563659809162626<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/9865246/pubmed" id="9865246" target="_blank">9865246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12503937">
<a name="12503937"></a>Butler TC, Rosen RM, Wallace AL, Amsden GW. Flumazenil and dialysis for gabapentin-induced coma. <i>Ann Pharmacother</i>. 2003;37(1):74-76. doi:10.1345/aph.1C242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/12503937/pubmed" id="12503937" target="_blank">12503937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11003118">
<a name="11003118"></a>Brammer G, Gilby R, Walter FG, et al. Continuous Intravenous Flumazenil Infusion for Benzodiazepine Poisoning. <i>Vet Hum Toxicol</i>. 2000;42(5):280-281.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/11003118/pubmed" id="11003118" target="_blank">11003118</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7755838">
<a name="7755838"></a>Chern CH, Chern TL, Hu SC, et al. Complete and Partial Response to Flumazenil in Patients With Suspected Benzodiazepine Overdose. <i>Am J Emerg Med</i>. 1995;13(3):372-375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/7755838/pubmed" id="7755838" target="_blank">7755838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9596422">
<a name="9596422"></a>Chern CH, Chern TL, Wang LM, et al. Continuous Flumazenil Infusion in Preventing Complications Arising From Severe Benzodiazepine Intoxication. <i>Am J Emerg Med</i>. 1998;16(3):238-241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/9596422/pubmed" id="9596422" target="_blank">9596422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16235515">
<a name="16235515"></a>Cienki JJ, Burkhart KK, Donovan JW. Zopiclone overdose responsive to flumazenil. <i>Clin Toxicol (Phila)</i>. 2005;43(5):385-386. doi:10.1081/clt-200058944<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/16235515/pubmed" id="16235515" target="_blank">16235515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7739960">
<a name="7739960"></a>Clark RF, Sage TA, Tunget C, et al. Delayed Onset Lorazepam Poisoning Successfully Reversed By Flumazenil in a Child: Case Report and Review of the Literature. <i>Pediatr Emerg Care</i>. 1995;11(1):32-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/7739960/pubmed" id="7739960" target="_blank">7739960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8319721">
<a name="8319721"></a>Cone AM, Nadel S, Sweeney B. Flumazenil reverses diazepam-induced neonatal apnoea and hypotonia. <i>Eur J Pediatr</i>. 1993;152(5):458-459. doi:10.1007/BF01955914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/8319721/pubmed" id="8319721" target="_blank">8319721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. <i>Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9512213">
<a name="9512213"></a>Dixon JC, Speidel BD, Dixon JJ. Neonatal Flumazenil Therapy Reverses Maternal Diazepam. <i>Acta Paediatr</i>. 1998;87(2):225-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/9512213/pubmed" id="9512213" target="_blank">9512213</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Flumazenil [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; August 2018.</div>
</li>
<li>
<div class="reference">
                  Flumazenil [prescribing information]. Rockford, IL: Mylan; November 2013.</div>
</li>
<li>
<div class="reference">
                  Ghouri AF, Ramirez Ruiz MA, White PF. Effect of Flumazenil on Recovery After Midazolam and Propofol Sedation. <i>Anesthesiology</i>. 1994;81(2):330-339.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23404347">
<a name="23404347"></a>Gunja N. The clinical and forensic toxicology of Z-drugs. <i>J Med Toxicol</i>. 2013;9(2):155-162. doi:10.1007/s13181-013-0292-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/23404347/pubmed" id="23404347" target="_blank">23404347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hansen.1">
<a name="Hansen.1"></a>Hansen AR, Stark AR, Eichenwald EC, Martin CR. <i>Cloherty and Stark's Manual of Neonatal Care</i>. 9th ed. Wolters Kluwer Health; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7696723">
<a name="7696723"></a>Haverkos GP, Di Salvo RP, Imhoff TE. Fatal Seizures After Flumazenil Administration in a Patient With Mixed Overdose. <i>Ann Pharmacother</i>. 1994;28(12):1347-1349.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/7696723/pubmed" id="7696723" target="_blank">7696723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3142220">
<a name="3142220"></a>Höjer J, Baehrendtz S. The effect of flumazenil (Ro 15-1788) in the management of self-induced benzodiazepine poisoning. A double-blind controlled study. <i>Acta Med Scand</i>. 1988;224(4):357-365. doi:10.1111/j.0954-6820.1988.tb19595.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/3142220/pubmed" id="3142220" target="_blank">3142220</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1686131">
<a name="1686131"></a>Höjer J, Baehrendtz S, Magnusson A, et al. A placebo-controlled trial of flumazenil given by continuous infusion in severe benzodiazepine overdosage. <i>Acta Anaesthesiol Scand</i>. 1991;35(7):584-590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/1686131/pubmed" id="1686131" target="_blank">1686131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12215053">
<a name="12215053"></a>Höjer J, Salmonson H, Sundin P. Zaleplon-induced coma and bluish-green urine: possible antidotal effect by flumazenil. <i>J Toxicol Clin Toxicol</i>. 2002;40(5):571-572. doi:10.1080/07313810.2002.11863667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/12215053/pubmed" id="12215053" target="_blank">12215053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23126253">
<a name="23126253"></a>Hood SD, Norman A, Hince DA, Melichar JK, Hulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil. <i>Br J Clin Pharmacol</i>. 2014;77(2):285-294.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/23126253/pubmed" id="23126253" target="_blank">23126253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Howland.1">
<a name="Howland.1"></a>Howland M. Flumazenil. In: Nelson LS, Howland M, Lewin NA, Smith SW, Goldfrank LR, Hoffman RS, eds. <i>Goldfrank's Toxicologic Emergencies.</i> 11th ed. McGraw-Hill Education; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22531190">
<a name="22531190"></a>Kreshak AA, Tomaszewski CA, Clark RF, Cantrell FL. Flumazenil administration in poisoned pediatric patients. <i>Pediatr Emerg Care</i>. 2012;28(5):448-450. doi:10.1097/PEC.0b013e3182531d0d<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/22531190/pubmed" id="22531190" target="_blank">22531190</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2111156">
<a name="2111156"></a>Lheureux P, Debailleul G, De Witte O, Askenasi R. Zolpidem intoxication mimicking narcotic overdose: response to flumazenil. <i>Hum Exp Toxicol</i>. 1990;9(2):105-107. doi:10.1177/096032719000900209<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/2111156/pubmed" id="2111156" target="_blank">2111156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33964989">
<a name="33964989"></a>Masciullo M, Pichiorri F, Scivoletto G, Foti C, Molinari M. Flumazenil therapy for a gabapentin-induced coma: a case report.<i> J Med Case Rep</i>. 2021;15(1):242. doi:10.1186/s13256-021-02816-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/33964989/pubmed" id="33964989" target="_blank">33964989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11327221">
<a name="11327221"></a>Mathieu-Nolf M, Babé MA, Coquelle-Couplet V, et al. Flumazenil Use in an Emergency Department: A Survey. <i>J Toxicol Clin Toxicol</i>. 2001;39(1):15-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/11327221/pubmed" id="11327221" target="_blank">11327221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14620397">
<a name="14620397"></a>Maxa JL, Ogu CC, Adeeko MA, Swaner TG. Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity. <i>Pharmacotherapy</i>. 2003;23(11):1513-1516. doi:10.1592/phco.23.14.1513.31941<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/14620397/pubmed" id="14620397" target="_blank">14620397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24619543">
<a name="24619543"></a>Moore PW, Donovan JW, Burkhart KK, et al. Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated deliriumtoxicity during treatment of alcohol withdrawal, a retrospective review at one center. <i>J Med Toxicol</i>. 2014;10(2):126-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/24619543/pubmed" id="24619543" target="_blank">24619543</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26324010">
<a name="26324010"></a>Nguyen TT, Troendle M, Cumpston K, Rose SR, Wills BK. Lack of adverse effects from flumazenil administration: an ED observational study. <i>Am J Emerg Med</i>. 2015;33(11):1677-1679.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/26324010/pubmed" id="26324010" target="_blank">26324010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7955804">
<a name="7955804"></a>Patat A, Naef MM, van Gessel E, Forster A, Dubruc C, Rosenzweig P. Flumazenil antagonizes the central effects of zolpidem, an imidazopyridine hypnotic. <i>Clin Pharmacol Ther</i>. 1994;56(4):430-436. doi:10.1038/clpt.1994.157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/7955804/pubmed" id="7955804" target="_blank">7955804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26096314">
<a name="26096314"></a>Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse events associated with flumazenil treatment for the management of suspected benzodiazepine intoxication--a systematic review with meta-analyses of randomised trials. <i>Basic Clin Pharmacol Toxicol</i>. 2016;118(1):37-44. doi:10.1111/bcpt.12434<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/26096314/pubmed" id="26096314" target="_blank">26096314</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8597142">
<a name="8597142"></a>Proudfoot AT. Antidotes: benefits and risks. <i>Toxicol Lett</i>. 1995;82-83:779-783.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/8597142/pubmed" id="8597142" target="_blank">8597142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33125517">
<a name="33125517"></a>Razavizadeh AS, Zamani N, Ziaeefar P, Ebrahimi S, Hassanian-Moghaddam H. Protective effect of flumazenil infusion in severe acute benzodiazepine toxicity: a pilot randomized trial. <i>Eur J Clin Pharmacol.</i> 2021;77(4):547-554. doi:10.1007/s00228-020-03031-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/33125517/pubmed" id="33125517" target="_blank">33125517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7655138">
<a name="7655138"></a>Reisner-Keller LA, Pham Z.Oral Flumazenil in the Treatment of Epilepsy. <i>Ann Pharmacother</i>. 1995;29(5):530-531.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/7655138/pubmed" id="7655138" target="_blank">7655138</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2005661">
<a name="2005661"></a>Richard P, Autret E, Bardol J, et al. The Use of Flumazenil in a Neonate. <i>J Toxicol Clin Toxicol</i>. 1991;29(1):137-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/2005661/pubmed" id="2005661" target="_blank">2005661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2512053">
<a name="2512053"></a>Roald OK, Dahl V. Flunitrazepam Intoxication in a Child Successfully Treated With the Benzodiazepine Antagonist Flumazenil. <i>Crit Care Med</i>. 1989;17(12):1355-1356.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/2512053/pubmed" id="2512053" target="_blank">2512053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33581937">
<a name="33581937"></a>Schult RF, Omar D, Wiegand TJ, Gordetsky RM, Acquisto NM. Experience with lower dose flumazenil at an academic medical center. <i>Am J Emerg Med</i>. 2021;49:399-401. doi:10.1016/j.ajem.2021.02.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/33581937/pubmed" id="33581937" target="_blank">33581937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1611650">
<a name="1611650"></a>Spivey WH. Flumazenil and Seizures: Analysis of 43 Cases. <i>Clin Ther</i>. 1992;14(2):292-305.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/1611650/pubmed" id="1611650" target="_blank">1611650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8177806">
<a name="8177806"></a>Sugarman JM, Paul RI. Flumazenil: a review. <i>Pediatr Emerg Care</i>. 1994;10(1):37-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/8177806/pubmed" id="8177806" target="_blank">8177806</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9468179">
<a name="9468179"></a>Trujillo MH, Guerrero J, Fragachan C, et al. Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration. <i>Crit Care Med</i>. 1998;26(2):377-391.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/9468179/pubmed" id="9468179" target="_blank">9468179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21785147">
<a name="21785147"></a>Veiraiah A, Dyas J, Cooper G, Routledge PA, Thompson JP. Flumazenil use in benzodiazepine overdose in the UK: a retrospective survey of NPIS data. <i>Emerg Med J</i>. 2012;29(7):565-569. doi:10.1136/emj.2010.095075<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/21785147/pubmed" id="21785147" target="_blank">21785147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9306053">
<a name="9306053"></a>Weinbroum AA, Flaishon R, Sorkine P, Szold O, Rudick V. A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. <i>Drug Saf</i>. 1997;17(3):181-196. doi:10.2165/00002018-199717030-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/9306053/pubmed" id="9306053" target="_blank">9306053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8605789">
<a name="8605789"></a>Weinbroum A, Rudick V, Sorkine P, et al. Use of flumazenil in the treatment of drug overdose: a double-blind and open clinical study in 110 patients. <i>Crit Care Med</i>. 1996;24(2):199-206. doi:10.1097/00003246-199602000-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/8605789/pubmed" id="8605789" target="_blank">8605789</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Williams.1">
<a name="Williams.1"></a>Williams JS, Lee MA, Schauben J, et al. Flumenazil revisited. <i>Ann Emerg Med</i>. 2008;51(4):473.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18788000">
<a name="18788000"></a>Yang CC, Deng JF. Utility of flumazenil in zopiclone overdose. <i>Clin Toxicol (Phila)</i>. 2008;46(9):920-921. doi:10.1080/15563650802043660<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/18788000/pubmed" id="18788000" target="_blank">18788000</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11349753">
<a name="11349753"></a>Zaw W, Knoppert DC, da Silva O. Flumazenil's Reversal of Myoclonic-Like Movements Associated With Midazolam in Term Newborns. <i>Pharmacotherapy</i>. 2001;21(5):642-646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/flumazenil-pediatric-drug-information/abstract-text/11349753/pubmed" id="11349753" target="_blank">11349753</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13307 Version 194.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
